Vanguard Group’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.41M | Hold |
110,215
| – | – | ﹤0.01% | 3682 |
|
|
2025
Q3 | $2.06M | Buy |
110,215
+3,977
| +4% | +$78.3K | ﹤0.01% | 3573 |
|
|
2025
Q2 | $2.72M | Buy |
106,238
+8,760
| +9% | +$176K | ﹤0.01% | 3429 |
|
|
2025
Q1 | $1.95M | Hold |
97,478
| – | – | ﹤0.01% | 3498 |
|
|
2024
Q4 | $1.77M | Hold |
97,478
| – | – | ﹤0.01% | 3601 |
|
|
2024
Q3 | $2.92M | Hold |
97,478
| – | – | ﹤0.01% | 3444 |
|
|
2024
Q2 | $1.37M | Hold |
97,478
| – | – | ﹤0.01% | 3690 |
|
|
2024
Q1 | $1.85M | Hold |
97,478
| – | – | ﹤0.01% | 3618 |
|
|
2023
Q4 | $2.16M | Hold |
97,478
| – | – | ﹤0.01% | 3578 |
|
|
2023
Q3 | $3.67M | Hold |
97,478
| – | – | ﹤0.01% | 3376 |
|
|
2023
Q2 | $7M | Sell |
97,478
-363
| -0.4% | -$23K | ﹤0.01% | 3141 |
|
|
2023
Q1 | $6.59M | Hold |
97,841
| – | – | ﹤0.01% | 3174 |
|
|
2022
Q4 | $3.03M | Buy |
97,841
+44
| +0% | +$1.31K | ﹤0.01% | 3514 |
|
|
2022
Q3 | $2.66M | Hold |
97,797
| – | – | ﹤0.01% | 3626 |
|
|
2022
Q2 | $4.28M | Sell |
97,797
-11,899
| -11% | -$546K | ﹤0.01% | 3458 |
|
|
2022
Q1 | $7M | Sell |
109,696
-762
| -0.7% | -$54.6K | ﹤0.01% | 3346 |
|
|
2021
Q4 | $9.26M | Buy |
110,458
+16,827
| +18% | +$1.89M | ﹤0.01% | 3258 |
|
|
2021
Q3 | $15.2M | Sell |
93,631
-11,997
| -11% | -$1.95M | ﹤0.01% | 3008 |
|
|
2021
Q2 | $16M | Buy |
105,628
+531
| +0.5% | +$89.5K | ﹤0.01% | 2952 |
|
|
2021
Q1 | $18.2M | Sell |
105,097
-5,983
| -5% | -$1.14M | ﹤0.01% | 2834 |
|
|
2020
Q4 | $17.7M | Buy |
111,080
+16,267
| +17% | +$2.72M | ﹤0.01% | 2699 |
|
|
2020
Q3 | $15.1M | Buy |
94,813
+15,172
| +19% | +$2.74M | ﹤0.01% | 2585 |
|
|
2020
Q2 | $15.8M | Buy |
79,641
+9,129
| +13% | +$1.68M | ﹤0.01% | 2540 |
|
|
2020
Q1 | $10.9M | Buy |
70,512
+289
| +0.4% | +$29.2K | ﹤0.01% | 2578 |
|
|
2019
Q4 | $5.41M | Sell |
70,223
-222
| -0.3% | -$19.4K | ﹤0.01% | 3144 |
|
|
2019
Q3 | $7.09M | Buy |
70,445
+1,660
| +2% | +$193K | ﹤0.01% | 3001 |
|
|
2019
Q2 | $9.09M | Buy |
68,785
+335
| +0.5% | +$46K | ﹤0.01% | 2913 |
|
|
2019
Q1 | $10.4M | Buy |
68,450
+3,314
| +5% | +$516K | ﹤0.01% | 2803 |
|
|
2018
Q4 | $10.5M | Buy |
65,136
+3,730
| +6% | +$741K | ﹤0.01% | 2752 |
|
|
2018
Q3 | $15.8M | Sell |
61,406
-1,382
| -2% | -$347K | ﹤0.01% | 2696 |
|
|
2018
Q2 | $14.3M | Buy |
62,788
+12,852
| +26% | +$2.43M | ﹤0.01% | 2723 |
|
|
2018
Q1 | $7.04M | Buy |
49,936
+7,357
| +17% | +$1.11M | ﹤0.01% | 2994 |
|
|
2017
Q4 | $5.54M | Buy |
42,579
+2,582
| +6% | +$328K | ﹤0.01% | 3095 |
|
|
2017
Q3 | $4.96M | Buy |
39,997
+17,394
| +77% | +$1.77M | ﹤0.01% | 3122 |
|
|
2017
Q2 | $1.94M | Sell |
22,603
-5,753
| -20% | -$504K | ﹤0.01% | 3388 |
|
|
2017
Q1 | $2.55M | Buy |
28,356
+1,066
| +4% | +$119K | ﹤0.01% | 3301 |
|
|
2016
Q4 | $2.98M | Sell |
27,290
-627
| -2% | -$68.6K | ﹤0.01% | 3231 |
|
|
2016
Q3 | $3.57M | Buy |
27,917
+1,032
| +4% | +$107K | ﹤0.01% | 3157 |
|
|
2016
Q2 | $2.45M | Buy |
26,885
+272
| +1% | +$23.7K | ﹤0.01% | 3302 |
|
|
2016
Q1 | $2.09M | Buy |
26,613
+1,210
| +5% | +$105K | ﹤0.01% | 3363 |
|
|
2015
Q4 | $2.83M | Buy |
25,403
+822
| +3% | +$112K | ﹤0.01% | 3255 |
|
|
2015
Q3 | $3.1M | Buy |
24,581
+709
| +3% | +$94.6K | ﹤0.01% | 3180 |
|
|
2015
Q2 | $2.93M | Buy |
23,872
+11,458
| +92% | +$1.56M | ﹤0.01% | 3250 |
|
|
2015
Q1 | $3.28M | Buy |
+12,414
| New | +$2.55M | ﹤0.01% | 3199 |
|
Other funds holding CTSO
CM
Vanguard Group's CTSO Position: Q4 2025 in Review
Vanguard Group held its Cytosorbents Corp (CTSO) position steady in Q4 2025 at 110,215 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3682.
Vanguard Group first reported a position in CTSO in Q1 2015 and has held it in 44 quarters since. The position peaked at $18.2M in Q1 2021. 51 funds tracked by Wall St. Rank hold CTSO as of Q4 2025.
- Vanguard Group held 110,215 shares of Cytosorbents Corp worth $1.41M as of Q4 2025.
- Vanguard Group left its Cytosorbents Corp share count unchanged in Q4 2025.
- Cytosorbents Corp made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3682 holding.
- Vanguard Group first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 44 quarters since.
- Vanguard Group's Cytosorbents Corp position peaked at $18.2M in Q1 2021.
- 51 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.